Company / Cash & Equivalents
Thermo Fisher Scientific Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$9.9B
FY2025
5-year range
$4.0B / $9.9B
FY2021-FY2025
Trend
+145.7%
vs FY2024
Sector context
#3 of 148
Health Care
What the data says
Among 148 Health Care companies, Thermo Fisher Scientific is in the top 2% for cash & equivalents. Cash & Equivalents returned to growth in FY2025 after 2 years of decline, reaching $9.9B.
Based on SEC 10-K filings.
$9.9B in FY2025 with a 5-year CAGR of -0.9%. Ranks 3rd among 148 companies in Health Care.
Improved from $8.1B to $9.9B over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +4.9%
- 5-Year CAGR
- -0.9%
- 10-Year CAGR
- -
Sector benchmark
Top 2% in Health CareTop 2% of 148This company $9.9B Sector average $1.2B
▼
+737.2% above sector average
Key checks
Key Insights
- 5-year CAGR of -0.9%, indicating a declining trend.
- In FY2025, cash & equivalents increased 145.7% year-over-year.
- Ranks #3 out of 148 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2020.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $9.9B | +145.7% |
| FY2024 | $4.0B | -50.4% |
| FY2023 | $8.1B | -5.2% |
| FY2022 | $8.5B | +90.4% |
| FY2021 | $4.5B | -56.6% |
| FY2020 | $10.3B | +330.4% |
| FY2019 | $2.4B | +14.1% |
| FY2018 | $2.1B | +57.5% |
| FY2017 | $1.3B | +69.8% |
| FY2016 | $786.0M | +73.9% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026